Ponatinib Drives Cardiotoxicity by S100A8/A9-NLRP3-IL-1β Mediated Inflammation
Circulation Research · 03.02.2023 · 132 (3) · 267-289
DOI: 10.1161/circresaha.122.321504 ↗Kurz gefasst
Fachartikel in der Zeitschrift Circulation Research, erschienen am 03.02.2023. Verfasst von Sultan Tousif und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiovascular Disease, UAB | The University of Alabama at Birmingham, Birmingham, AL (S.T., A.P.S., P.U., A.T.C., Q.Z., H.L.). Hauptthemen laut MEDLINE: Cardiotoxicity, Heart Diseases. Die Arbeit wurde bisher 75-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS.
Abstract (Originalsprache)
Background
The tyrosine kinase inhibitor ponatinib is the only treatment option for chronic myelogenous leukemia patients with T315I (gatekeeper) mutation. Pharmacovigilance analysis of Food and Drug Administration and World Health Organization datasets has revealed that ponatinib is the most cardiotoxic agent among all Food and Drug Administration–approved tyrosine kinase inhibitors in a real-world scenario. However, the mechanism of ponatinib-induced cardiotoxicity is unknown.
Methods
The lack of well-optimized mouse models has hampered the in vivo cardio-oncology studies. Here, we show that cardiovascular comorbidity mouse models evidence a robust cardiac pathological phenotype upon ponatinib treatment. A combination of multiple in vitro and in vivo models was employed to delineate the underlying molecular mechanisms.
Results
An unbiased RNA sequencing analysis identified the enrichment of dysregulated inflammatory genes, including a multifold upregulation of alarmins S100A8/A9, as a top hit in ponatinib-treated hearts. Mechanistically, we demonstrate that ponatinib activates the S100A8/A9-TLR4 (Toll-like receptor 4)-NLRP3 (NLR family pyrin domain–containing 3)-IL (interleukin)-1β signaling pathway in cardiac and systemic myeloid cells, in vitro and in vivo, thereby leading to excessive myocardial and systemic inflammation. Excessive inflammation was central to the cardiac pathology because interventions with broad-spectrum immunosuppressive glucocorticoid dexamethasone or specific inhibitors of NLRP3 (CY-09) or S100A9 (paquinimod) nearly abolished the ponatinib-induced cardiac dysfunction.
Conclusions
Taken together, these findings uncover a novel mechanism of ponatinib-induced cardiac inflammation leading to cardiac dysfunction. From a translational perspective, our results provide critical preclinical data and rationale for a clinical investigation into immunosuppressive interventions for managing ponatinib-induced cardiotoxicity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cardiovascular Disease, UAB | The University of Alabama at Birmingham, Birmingham, AL (S.T., A.P.S., P.U., A.T.C., Q.Z., H.L.).
- Department of Biology, Western Kentucky University, Bowling Green, KY (C.G., N.W.).
- Division of Cardiology, Department of Medicine, Washington University in St. Louis (S.D.P.).
ORCID-Profile: Anand P Singh, Prachi Umbarkar, Nicholas Wheeler, Angelica Toro Cora, Sumanth D Prabhu, Hind Lal
Förderung
- NHLBI NIH HHS
Zitieren
APA
Tousif, S., Singh, A. P., Umbarkar, P., Galindo, C., Wheeler, N., Toro Cora, A., Zhang, Q., Prabhu, S. D., & Lal, H. (2023). Ponatinib Drives Cardiotoxicity by S100A8/A9-NLRP3-IL-1β Mediated Inflammation. Circulation Research, 132(3), 267-289. https://doi.org/10.1161/circresaha.122.321504
Vancouver
Tousif S, Singh AP, Umbarkar P, Galindo C, Wheeler N, Toro Cora A, et al. Ponatinib Drives Cardiotoxicity by S100A8/A9-NLRP3-IL-1β Mediated Inflammation. Circulation Research. 2023;132(3):267-289. doi:10.1161/circresaha.122.321504
BibTeX
@article{Tousif2023,
author = {Tousif, Sultan and Singh, Anand P and Umbarkar, Prachi and Galindo, Cristi and Wheeler, Nicholas and Toro Cora, Angelica and Zhang, Qinkun and Prabhu, Sumanth D and Lal, Hind},
title = {Ponatinib Drives Cardiotoxicity by S100A8/A9-NLRP3-IL-1β Mediated Inflammation},
journal = {Circulation Research},
year = {2023},
volume = {132},
number = {3},
pages = {267--289},
doi = {10.1161/circresaha.122.321504}
}
EUVIMED